Table 1. Demographic and clinical background of the study sample.
| SCZ n=104 | AD n=100 | HC n=142 | Total N=346 | Test statistic | ||
|---|---|---|---|---|---|---|
| F/χ² | P | |||||
| Gender (m/f) | 63/41 | 43/57 | 84/58 | 190/156 | χ²=8.1 | 0.02 |
| Age, years: mean (s.d.) | 31.5 (8.9) | 33.2 (11.2) | 33.4 (8.4) | 32.8 (9.5) | F=1.44 | 0.24a |
| Left amygdala activation (COPE): mean (s.d.) | 11.6 (13.7) | 12.3 (13.1) | 11.0 (12.9) | 11.6 (12.9) | χ²=0.73 | 0.69b |
| Right amygdala activation (COPE): mean (s.d.) | 12.1 (15.4) | 12.6 (13.6) | 12.3 (11.7) | 12.3 (13.4) | χ²=0.19 | 0.91b |
| Medicatedc N (%) | 91 (87.5) | 80 (80) | – | – | – | – |
| AP/LIT/AE/AD/HYPd (N) | 88/1/21/32/12 | 47/10/39/31/13 | – | – | – | – |
| Rs2254298 (maf, Ae) | 0.11 | 0.19 | 0.10 | 0.10 | – | – |
| Rs53576 (maf, A) | 0.29 | 0.28 | 0.32 | 0.30 | – | – |
| Rs237902 (maf, A) | 0.31 | 0.42 | 0.35 | 0.36 | – | – |
| Behavioural data | ||||||
| Response timef (ms): mean (s.d.) | 1192.8 (314.9) | 1197.6 (339) | 1069.9 (230.9) | 1141 (295.3) | χ²=13.6 | 0.001 |
| Accuracy ratef (%): mean (s.d.) | 98.7 (0.06) | 98.5 (0.09) | 99.2 (0.03) | 98.9 (0.06) | χ²=0.29 | 0.87 |
SCZ, schizophrenia spectrum disorders; AD, affective spectrum disorders; HC, healthy controls; COPE, contrast parameter estimates; maf, minor allele frequency.
Brown–Forsythe test on log-transformed age.
Non-parametric Kruskal–Wallis test.
Regular use of psychopharmacological medication.
Regular use of antipsychotics/lithium/anti epileptics/anti-depressives/hypnotics.
The minor allele frequency of the A allele.
Complete behavioural data (response time and accuracy rate) were available for 89 SCZ, 94 AD and 140 HC. For the remaining individuals (SCZ 15, AD 6, HC 2) an accuracy rate (i.e. combined rate for negative and shapes) was available and was used to confirm that the participants paid attention to the task (accuracy rate 96.2%, 96.3% and 93.5%, respectively).